Exploring Merkel Cell Carcinoma Clinical Trial Engagement Patterns
Part of paid clinical trials in San Francisco, California.
- Sponsor
- Power Life Sciences Inc.
- Study ID
- NCT06039033
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Merkel Cell Carcinoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
Taking part in medical research usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups. This study will admit a wide range of data on the clinical trial experience of Merkel cell carcinoma patients to determine which factors prevail in limiting a patient's ability to join or finish a trial. It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future Merkel cell carcinoma patients.
Key Dates
- Start date
- Oct 31, 2024
- Status verified
- Sep 2023
- Primary completion
- Oct 31, 2025
- Completion
- Oct 31, 2026
Study Design
- Enrollment
- 500 participants (estimated)
Primary Outcome Measure
Number of patients who decide to enroll in a Merkel cell carcinoma clinical research [ Time Frame: 3 months ]
Central Contacts
- Michael B Gill415-900-4227
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Power Life Sciences | San Francisco | California | 94107 |
Find similar trials in San Francisco, CA
Related Studies
- A Beta-only IL-2 ImmunoTherapY StudyPHASE1/PHASE2 · Recruiting · Medicenna Therapeutics, Inc. · San Diego, California
- Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisPHASE1/PHASE2 · Recruiting · Neonc Technologies, Inc. · Beverly Hills, California
- Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC VirusPHASE2 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas
- Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell CarcinomaPHASE1 · Recruiting · H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida